RxDoctor Payments Data

Erin Tofani, APRN

Family · Indianapolis, INNPI 1548776925

Payments from drug & device makers

$404in general payments, 2019–2025

Across 14 payments — averaging $28.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$130
  • Otsuka America Pharmaceutical, Inc.$128
  • Sunovion Pharmaceuticals Inc.$96
  • Takeda Pharmaceuticals U.S.A., Inc.$32
  • Viatris Specialty LLC$19

What the payments were for

  • Food & beverage$404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$404 in reported general payments places this provider in the 50th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$354,468
Medicare patients
412
Services billed
4,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban337$127,927
TrulicityDulaglutide48$35,442
TradjentaLinagliptin101$32,104
FarxigaDapagliflozin Propanediol63$23,787
OzempicSemaglutide13$14,645
MyrbetriqMirabegron31$12,151
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen458$9,930
Pantoprazole Sodium599$9,294
JardianceEmpagliflozin20$9,199
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$8,078
Lantus SolostarInsulin Glargine,hum.Rec.Anlog116$6,864
XareltoRivaroxaban13$6,858
Duloxetine Hcl210$6,345
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc61$6,233
Potassium Chloride294$5,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$130$6,85813 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$32$2,69711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,392 family providers in Indiana.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →